Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61–62
HOS-134629 · Präparat HOS-097580
61 INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by Interaction Recommendations concerning co- therapeutic areas Geometric mean change (%) administration Pravastatin pravastatin AUC ↑ 81% ¶ When administration of pravastatin 40 mg single dose pravastatin Cmin ND and boosted darunavir is required, it pravastatin Cmax ↑ 63% is recommended to start with the ¶ an up to five-fold increase was lowest possible dose of pravastatin seen in a limited subset of subjects and titrate up to the desired clinical effect while monitoring for safety. ║ Rosuvastatin rosuvastatin AUC ↑ 48% When administration of rosuvastatin 10 mg once daily rosuvastatin Cmax ↑ 144%║ and boosted darunavir is required, it ║ based on published data with is recommended to start with the darunavir/ritonavir lowest possible dose of rosuvastatin and titrate up to the desired clinical rosuvastatin AUC ↑ 93%§ effect while monitoring for safety. rosuvastatin Cmax ↑ 277% §
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) ritonavir (HOS-084521) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 3659193a40a75a5af4ede765839e9be01ae7da76b6293d3fe4467b98d3f12083 · Zeichen 59103–60634 im Abschnitt